Scarica l'app Stockscreener
35.92
2.25%
0.79
Dopo l'orario di chiusura:
35.92
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
292,569 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Emerald Advisers LLC - MarketBeat
Spyre Therapeutics Announces Grants of Inducement Awards - StockTitan
Spyre Therapeutics to Participate in Upcoming November Investor Conferences - StockTitan
Spyre Therapeutics (NASDAQ:SYRE) Price Target Increased to $65.00 by Analysts at Guggenheim - Defense World
Spyre Therapeutics director sells shares worth $10,929 - Investing.com
Spyre Therapeutics director sells shares worth $10,929 By Investing.com - Investing.com South Africa
Jeffrey W. Albers Sells 300 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock - MarketBeat
Spyre Therapeutics' Catalyst Cascade On Track For Late 2024 - RTTNews
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap UpHere's Why - MarketBeat
Assenagon Asset Management S.A. Acquires New Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $43.43 - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 4.5%Time to Buy? - MarketBeat
Results from Spyre Therapeutics Inc. (SYRE) show potential - US Post News
Wedbush’s latest rating for SYRE stock - Knox Daily
SYRE’s 2023 Market Dance: Up 42.47% – Time to Invest? - The InvestChronicle
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $43.43 Consensus PT from Analysts - MarketBeat
Wells Fargo reiterates price target on Spyre shares, optimistic on SPY003 By Investing.com - Investing.com Canada
Spyre shares rise on positive SPY003 data, analyst maintains Buy By Investing.com - Investing.com UK
Spyre Therapeutics advances IBD antibody treatments - Investing.com
Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations - PR Newswire
The Manufacturers Life Insurance Company Takes $888,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics (SYRE) Price Target Increased by 5.00% to 42.84 - MSN
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 3.5%Here's Why - MarketBeat
SYRESpyre Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Spyre Therapeutics (NASDAQ:SYRE) Trading 2.5% Higher - MarketBeat
Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter
Spyre Therapeutics names new Chief Medical Officer By Investing.com - Investing.com South Africa
Spyre Therapeutics names new Chief Medical Officer - Investing.com
Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting (SYRE) - Seeking Alpha
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 7.6% - MarketBeat
Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer - PR Newswire
Market Watch: Spyre Therapeutics Inc. (SYRE)’s Noteworthy Drop, Closing at 28.49 - The Dwinnex
There is no way Spyre Therapeutics Inc. (SYRE) can keep these numbers up - SETE News
Recent Insider Activity Suggests Potential Gains for Spyre Therapeutics Inc. (SYRE) - Knox Daily
Perceptive Advisors LLC Grows Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
687,080 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Bought by Driehaus Capital Management LLC - MarketBeat
Driehaus Capital Management LLC Invests $16.15 Million in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Ensign Peak Advisors Inc Invests $1.94 Million in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Armistice Capital LLC Purchases New Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
452,040 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Darwin Global Management Ltd. - MarketBeat
Affinity Asset Advisors LLC Purchases New Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 4.1% - Defense World
575,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Bought by Logos Global Management LP - Defense World
Ratios Uncovered: Breaking Down Spyre Therapeutics Inc. (SYRE)’s Trailing Twelve Months Metrics - The Dwinnex
Spyre Therapeutics Inc.’s results are impressive - US Post News
Great Point Partners LLC Purchases Shares of 134,612 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Integral Health Asset Management LLC Buys New Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
100,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Integral Health Asset Management LLC - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down to $30.17 - Defense World
Avoro Capital Advisors LLC Purchases Shares of 1,839,138 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Rhumbline Advisers Purchases Shares of 51,896 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Trading 4.3% Higher - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 4.3% - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of "Buy" from Analysts - MarketBeat
Spruce Biosciences Inc’s results are impressive - US Post News
SciSparc advances phase IIb trial for Tourette Syndrome treatment By Investing.com - Investing.com Australia
Financial Fitness Check: Examining Spruce Biosciences Inc (SPRB)’s Key Ratios - The Dwinnex
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):